Opinion: Medicare Prosthesis Bill Needs Cost and Quality Standards
A bipartisan House bill would add Medicare coverage for custom breast prostheses after mastectomy, widening patient choice while raising questions about price, eligibility and product standards.
Representatives Judy Chu and Mariannette Miller-Meeks reintroduced a bipartisan bill on October 30 to cover custom-fabricated breast prostheses under Medicare. Giving mastectomy patients a nonsurgical option that better fits their bodies is a reasonable coverage goal. Congress should move the proposal through committee with a credible cost estimate, clinical and manufacturing standards, clear eligibility rules and protections against inflated billing.
What the release says
The Breast Cancer Patient Equity Act is a proposal, not enacted law, and would expand Medicare coverage to custom-fabricated breast prostheses.
The sponsors say Medicare already covers traditional prostheses and surgical reconstruction but does not cover the custom nonsurgical option on equivalent terms.
The release cites more than four million U.S. women with a history of breast cancer, an estimated 321,910 invasive diagnoses in 2026 and more than 100,000 mastectomies each year; it does not provide a federal cost estimate.
Read the official release: Reps. Chu, Miller-Meeks Reintroduce Bipartisan Bill to Close Medicare Coverage Gap for Breast Cancer SurvivorsOur centrist perspective
The bill addresses a choice gap rather than requiring reconstruction. That distinction matters for patients who cannot undergo another operation or prefer a nonsurgical option.
Coverage rules should define when customization is medically appropriate, what qualifications suppliers must meet and how Medicare will establish prices without encouraging unnecessary or overpriced products.
Committee review can test whether better fit and comfort improve daily function and whether coverage reduces other medical costs, while preserving beneficiary choice among available options.
The tradeoffs
Broader coverage could reduce out-of-pocket costs and expand post-mastectomy choice, while adding Medicare spending that should be estimated before passage.
Custom products may improve fit and comfort, but weak supplier and billing standards could expose beneficiaries and taxpayers to inconsistent quality or excessive prices.
What to watch next
- Committee action, a Congressional Budget Office estimate and the coverage criteria proposed for beneficiaries and suppliers.
- Quality standards, payment methodology and evidence on access, patient experience and utilization after any implementation.
This is an editorial interpretation, not an official agency statement. Factual summaries rely on the linked release; implications and recommendations are our opinion. How we work